We have located links that may give you full text access.
In vitro activities of 'new' and 'conventional' antibiotics against multi-drug resistant Gram negative bacteria from patients in the intensive care unit.
Pathology 2007 December
OBJECTIVES: To identify and collect clinical isolates of multi-drug resistant Gram negative bacteria and to perform antimicrobial susceptibility testing using an extended panel of antibiotics including tigecycline, colistin, aztreonam, piperacillin/tazobactam and ampicillin/sulbactam.
METHODS: Minimum inhibitory concentrations (MICs) using the Epsilometer test (E-test) methodology were determined for 28 distinct multi-drug resistant Gram negative isolates from patients in the intensive care unit (ICU).
RESULTS: Tigecycline had good in vitro activity against Acinetobacter species and Enterobacter cloacae, and colistin had potent in vitro activity against Acinetobacter, E. cloacae and Pseudomonas aeruginosa. Enterobacter cloacae and Serratia marcescens but not P. aeruginosa or Acinetobacter species were susceptible to piperacillin/tazobactam. Ampicillin/sulbactam had poor in vitro activity for most isolates tested. The activity of tigecycline and colistin did not appear to be affected by the presence of extended spectrum beta-lactamases (ESBLs) and metallo-beta-lactamases (MBLs) and aztreonam maintained its in vitro activity against the Enterobacteriaceae tested despite the presence of MBLs.
CONCLUSIONS: Tigecycline and colistin have potent in vitro activity and might have useful therapeutic activity in patients with infections due to multi-drug resistant Acinetobacter species and E. cloacae, including those harbouring ESBLs and MBLs. In addition, colistin demonstrated potent in vitro activity against multi-drug resistant P. aeruginosa.
METHODS: Minimum inhibitory concentrations (MICs) using the Epsilometer test (E-test) methodology were determined for 28 distinct multi-drug resistant Gram negative isolates from patients in the intensive care unit (ICU).
RESULTS: Tigecycline had good in vitro activity against Acinetobacter species and Enterobacter cloacae, and colistin had potent in vitro activity against Acinetobacter, E. cloacae and Pseudomonas aeruginosa. Enterobacter cloacae and Serratia marcescens but not P. aeruginosa or Acinetobacter species were susceptible to piperacillin/tazobactam. Ampicillin/sulbactam had poor in vitro activity for most isolates tested. The activity of tigecycline and colistin did not appear to be affected by the presence of extended spectrum beta-lactamases (ESBLs) and metallo-beta-lactamases (MBLs) and aztreonam maintained its in vitro activity against the Enterobacteriaceae tested despite the presence of MBLs.
CONCLUSIONS: Tigecycline and colistin have potent in vitro activity and might have useful therapeutic activity in patients with infections due to multi-drug resistant Acinetobacter species and E. cloacae, including those harbouring ESBLs and MBLs. In addition, colistin demonstrated potent in vitro activity against multi-drug resistant P. aeruginosa.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app